Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769896 | 0.93 | RAB9A (0.47) | RAB9AROCK2MEN1KMT2ASPR | |
| SCHEMBL4773462 | 0.85 | LMNA (0.39) | RAB9AMEN1KMT2ANOTUM | |
| SCHEMBL508668 | 0.84 | HPGD (0.42) | RAB9AMEN1KMT2A | |
| SCHEMBL4766432 | 0.79 | MEN1 (0.45) | RAB9AROCK2MEN1KMT2ANOTUM | |
| SCHEMBL508731 | 0.78 | P2RX7 (0.41) | — | |
| SCHEMBL10254128 | 0.78 | P2RX7 (0.41) | — | |
| SCHEMBL14291275 | 0.76 | ALDH1A1 (0.42) | RAB9AROCK2MEN1KMT2ANOTUM | |
| SCHEMBL5225140 | 0.74 | KMT2A (0.47) | RAB9AROCK2MEN1KMT2A | |
| SCHEMBL14599716 | 0.74 | KCNH2 (0.40) | — | |
| SCHEMBL5225036 | 0.73 | LMNA (0.41) | MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | ROCK1 3435/4885RAB9A 2118/4885BCHE 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.